Figure 2.

The influence of the patients’ CYP3A4 expression and CYP3A5 genotype on serum clozapine concentrations. (A) Clozapine concentrations normalized by the dose and the bodyweight in CYP3A5 expressers (CYP3A5*1/*3) and nonexpresser patients expressing CYP3A4 at low, normal, and high levels, and (B) linear models for low (triangles) and normal/high (points) CYP3A4 expresser patients. The black points (A) indicate low CYP3A4 expresser patients carrying CYP3A5*1. The white point (A) indicates a high CYP3A4 expresser patient carrying CYP3A5*1. *P<.0001. GAPDH, glyceraldehide 3-phosphate dehydrogenase.